Recent clinical evidence showed that cancer patients with BRCA1/2 mutations (germline or somatic) were particularly sensitive to poly(ADP-ribose) polymerase inhibitors (PARPi)[7–8] and DNA damaging chemotherapy (e.g., platinum [9]). Here, BRCA1 is linked to cancer.